Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
The entire process takes less than 5 minutes
doi: 10.1210/jc.2014-4560 146 DelivanisDAGustafsonMPBornschleglSMertenMMKottschadeLWithersSet al
Mild to moderate pain Protocol: BPC-157: 250mcg twice daily Duration: 4-8 weeks Method: Injectable near pain site or systemic Expected outcome: 40-60% pain reduction Improved function May be sufficient alone Severe or chronic pain Protocol: BPC-157: 500mcg twice daily TB-500: 5-10mg weekly loading for 4-6 weeks, then 2-5mg maintenance Duration: 12-16 weeks minimum Method: Injectable Expected outcome: 50-70% pain reduction Significant functional improvement Better quality of life Multiple pain sites or systemic pain Protocol: BPC-157: 250-500mcg twice daily (systemic injections - abdomen/thighs) TB-500: 5mg weekly Optional: KPV 500mcg daily if inflammation major factor Duration: 12-24 weeks Expected outcome: 40-60% overall pain reduction Improved multiple areas Better mobility Maintenance protocol After initial relief: BPC-157: 250mcg daily OR every other day TB-500: 2-5mg weekly OR biweekly Duration: Ongoing as needed Why maintenance: Prevents pain return Continues healing Safe long-term Use our peptide dosing guide , peptide dosage chart , and how to calculate peptide dosages
Our team grounds your journey in real science and world-class aesthetic training
Importantly, tirzepatide carries a boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
17 Obstructive sleep apnoea, an independent risk factor associated with increased incidence of BO
